Table 4.

Univariate analyses for overall survival in the matched population.

	Univariate analyses
Variables	p value	HR (95% CI)
Men	0.19	1.36 (0.86–2.16)
Age	0.56	1.01 (0.98–1.03)
Performance status
1 versus 0	0.89	1.04 (0.61–1.76)
2 versus 0	0.06	2.22 (0.97–5.1)
Tumour location
Head (ref)	1	1
Body	0.07	0.59 (0.34–1.05)
Tail	0.85	0.95 (0.55–1.65)
Number of metastatic sites >1	0.65	1.13 (0.67–1.89)
Peritoneal carcinomatosis	0.76	1.08 (0.66–1.79)
Liver metastases	0.07	1.76 (0.95–3.28)
Pulmonary metastases	0.2	0.65 (0.33–1.26)
Lymph node metastases	0.5	1.25 (0.66–2.38)
Bone metastases	0.85	1.12 (0.35–3.57)
CA19.9 at baseline	0.002	1 (1–1)
Albumin	0.4	0.98 (0.95–1.02)
Bilirubin	0.43	1 (1–1.01)
Folfirinox versus gemcitabine/nab-paclitaxel	0.099	0.67 (0.42–1.08)

CI, confidence interval; HR, hazard ratio.